Experimental and therapeutic medicine最新文献

{"title":"Pathophysiological mechanisms and benefits of SGLT?2 inhibitors in a patient with cerebral artery aneurysm: A case report.","authors":"Oana-Andreea Parli Eanu, Roxana-Maria Nemes, Mara Amalia Balteanu, Daniel Radu, George Gherlan","doi":"10.3892/etm.2025.12862","DOIUrl":"10.3892/etm.2025.12862","url":null,"abstract":"<p><p>The present study described the case of a 50-year-old male patient. The patient had type 2 diabetes since the age of 38 years (in 2013) with an initial elevated glycated hemoglobin A1c of 7.2%, with a significant cardiovascular (CV) history consisting of an aneurysm of the anterior communicating artery that had been operated on in 1998 and a ruptured basilar artery tip aneurysm embolized with a stent in 2013; the case was also associated with bronchiectasis (since 2020), non-alcoholic fatty liver disease (since 2018), diabetic neuropathy (since 2023) and obesity with a body mass index of 31.72 kg/m² (since 2010). Over the years the patient exhibited good metabolic control, initially treated with Metformin and managed through a change of diet. However, due to intolerance to Metformin, the patient stopped receiving treatments and only managed his diet. Since diabetes is by definition a condition that implies a high CV risk by itself, the primary focus with this patient was to provide additional CV protection, particularly secondary protection against any other potential future, and possibly fatal, CV events. After a brief introduction regarding the available therapeutic options, the case is presented along with the medical history, concomitant medications and evolution after 1 year. In the discussion section, similar documented cases in the literature were compared with the present case, and the potential effects of the therapeutic intervention in the present study were compared.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"29 6","pages":"112"},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the anti‑influenza potential of Eucommiae Cortex based on bioinformatics analysis: <i>In silico</i> and <i>in vitro</i> experiments.","authors":"Aleksandra Nowakowska, Minjee Kim","doi":"10.3892/etm.2025.12856","DOIUrl":"https://doi.org/10.3892/etm.2025.12856","url":null,"abstract":"<p><p>Influenza infections damage the airway and induce the innate immune response that contributes to hyper-inflammation. Eucommiae Cortex (EC) enhances immune function and suppresses inflammation. To determine potential compounds and targets of EC associated with influenza, bioinformatics analyses and experimental verification were employed. The active compounds of EC were retrieved from the Traditional Chinese Medicine Systems Pharmacology database. The intersecting targets of EC and influenza were determined and examined using network pharmacology to analyze the relationship between the compounds and disease targets. The network identified three main compounds (quercetin, genistein and kaempferol) and four main targets (IL6, BCL2, IL1B and TNF). The ligand-target binding affinity was calculated by molecular docking, a computational method used in drug design to predict the interaction between the compound and protein target. The docking results revealed that kaempferol and TNF showed the strongest binding affinity. <i>In vitro</i> experiments confirmed the therapeutic effect of EC in influenza virus-infected Madin-Darby canine kidney cells. Collectively, the present study identified the active compounds and potential targets of EC in influenza and suggested EC as a future influenza treatment.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"29 5","pages":"106"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of rapid expansion combined with maxillary protraction therapy in patients at different growth phases: A retrospective study.","authors":"Xiaowen Yang, Yanan Chen, Chuqin Miao, Weiying Zheng","doi":"10.3892/etm.2025.12855","DOIUrl":"https://doi.org/10.3892/etm.2025.12855","url":null,"abstract":"<p><p>The best timing for treating adolescent patients with skeletal class III malocclusion is still unclear. The present study aimed to explore variations in the efficacy of rapid expansion combined with maxillary protraction therapy in patients with skeletal class III malocclusion at different growth and development stages. Clinical records of 45 patients with skeletal class III malocclusion who underwent rapid expansion combined with maxillary protraction therapy from January 2019 to June 2022 were included in the present study. Based on the cervical vertebral maturation method (CVM), the patients were retrospectively divided into three groups: Pre-pubertal (CVM stages I-II, n=15), pubertal (CVM stage III, n=15) and post-pubertal (CVM stages IV-VI, n=15). Lateral head radiographs before and after the treatment and various bone, dental and soft tissue measurements were compared between groups to assess the differences in treatment effects. The results of the intra-group comparison before and after the treatment showed that the dental and bone indicators, such as A Point-Nasion-Point B angle, sella-nasion-A point angle, sella-nasion-B point angle, mandibular plane angle, A Point-VR plane and anterior Nasal-VR plane (ANS-VR) were significantly different compared with those before treatment in all three groups of patients (P<0.05). The posterior Nasal-VR plane (PNS-VR) changed significantly in the pre-pubertal and pubertal groups (P<0.05), but there was no significant change in the post-pubertal group. The Glabella-Pronasale-Pogonion of soft tissue and Sella-Nasion-Nasion-Bs Point angle decreased significantly post-treatment in the three groups, while the Sella-Nasion-Nasion-Sn Point angle increased (P<0.05). Intergroup comparisons before and after treatment showed that there was no significant difference in the post-treatment indexes between the pre-pubertal and pubertal groups. The changes in ANS-VR and PNS-VR values before and after treatment were statistically significant between the post-pubertal and the other two groups (P<0.05). In conclusion, rapid expansion combined with maxillary protraction therapy has the best treatment effects in patients in the pre-pubertal and pubertal stages and is associated with significant skeletal effects and less alveolar response. Although the skeletal treatment effects are less favorable in patients in the post-pubertal stage with more pronounced alveolar responses, the treatment can still provide appropriate compensation for facial deformities and reduce the likelihood of orthognathic surgery.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"29 5","pages":"105"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti?atherosclerotic effect of aged garlic extract: Mode of action and therapeutic benefits (Review).","authors":"Satomi Miki, Miyuki Takashima, Jun-Ichiro Suzuki","doi":"10.3892/etm.2025.12854","DOIUrl":"10.3892/etm.2025.12854","url":null,"abstract":"<p><p>Atherosclerosis, a chronic inflammatory disease characterized by plaque buildup within the arteries that obstructs blood flow and significantly increases the morbidity and mortality rates associated with cardiovascular diseases caused by impaired blood flow due to vascular stenosis or occlusion, such as angina and myocardial infarction. The development of atherosclerosis involves a complex interplay of endothelial dysfunction, accumulation of oxidized low-density lipoprotein and macrophage-driven inflammation. The risk factors for atherosclerosis include chronic inflammation, hyperlipidemia and hypertension. Effective management of these risk factors can prevent and delay the onset and progression of atherosclerosis. Garlic and its processed preparations have previously been utilized to mitigate cardiovascular risk factors and continue to be used in traditional medicine in several countries. Among these preparations, aged garlic extract (AGE) has been shown to improve atherosclerosis in clinical trials and animal studies. AGE contains various compounds with potential anti-atherosclerotic properties, such as <i>S</i>-1-propenylcysteine, <i>S</i>-allylcysteine and other sulfur-containing constituents, which may help prevent the development and progression of atherosclerosis. The present manuscript reviewed and discussed the anti-atherogenic effect of AGE and its constituents by highlighting their mode of action and potential benefits for prevention and therapy in the management of atherosclerosis.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"29 5","pages":"104"},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics of sulfur?containing compounds in aged garlic extract: <i>S</i>?Allylcysteine, <i>S</i>?1?propenylcysteine, <i>S</i>?methylcysteine, <i>S</i>?allylmercaptocysteine and others (Review).","authors":"Masato Nakamoto, Kayo Kunimura, Masahiro Ohtani","doi":"10.3892/etm.2025.12852","DOIUrl":"10.3892/etm.2025.12852","url":null,"abstract":"<p><p>Aged garlic extract (AGE) is produced by aging raw garlic (<i>Allium sativum L.</i>) in an alcoholic solution for >10 months. AGE is rich in sulfur-containing amino acids, such as <i>S</i>-allylcysteine (SAC), <i>S</i>-1-propenylcysteine (S1PC), <i>S</i>-methylcysteine (SMC) and <i>S</i>-allylmercaptocysteine (SAMC). These sulfur-containing amino acids exert various beneficial pharmacological effects and have different pharmacokinetic properties. For instance, SAC, S1PC and SMC are well absorbed in rats with high bioavailability (88.0-95.8%), whereas SAMC is not detected in the plasma after oral administration. Orally administered SAC and S1PC are excreted in urine in their <i>N</i>-acetylated forms and ~50% of SMC is excreted as inorganic sulfur compounds, whereas SAMC immediately reacts with blood and is metabolized into volatile sulfur compounds. The present review summarizes and discusses the pharmacokinetic profiles (absorption, distribution, metabolism and excretion) of sulfur-containing compounds present in AGE and other garlic-derived substances, such as allicin.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"29 5","pages":"102"},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare and challenging pediatric case of drug toxicity and immune reconstitution inflammatory syndrome during the treatment of intracranial tuberculoma: A case report.","authors":"Fatma Tuğba Çetin, Ümmühan Çay, Fatma Kilinç, Ömer Kaya, Nisanur Tapaç, Emel Bakanoğlu, Asena Ünal, Özlem Özgür Gündeşlioğlu, Arzu Demir, Derya Alabaz","doi":"10.3892/etm.2025.12815","DOIUrl":"10.3892/etm.2025.12815","url":null,"abstract":"<p><p>Intracranial tuberculoma represents one of the most severe complications of central nervous system tuberculosis (TB), with an incidence that is relatively low. In cases of intracranial tuberculoma, patients may develop drug toxicity and/or immune reconstitution inflammatory syndrome (IRIS) while receiving anti-TB treatment. The current study presented the case of a seven-year-old female patient with intracranial tuberculoma who developed drug-induced hepatotoxicity and IRIS during the course of treatment. During the follow-up of the patient, anti-TB drug-induced hepatitis developed, which led to the discontinuation of the drug twice. In the seventh month of treatment, cranial MRI showed the progression of tuberculoma lesions. The possibility of IRIS or treatment failure was considered and the treatment was restarted with steroids and non-hepatotoxic anti-TB drugs. With steroid and anti-TB treatment, the lesions regressed almost completely and the neurological deficit regressed. Patients receiving treatment should be followed up closely due to the possible side effects of anti-TB drugs, especially IRIS, which develops as an immune restructuring response during the recovery of the immune system.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"29 4","pages":"66"},"PeriodicalIF":0.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of overexpression of <i>GRN</i> on the proliferation and osteogenic capacity of human periodontal cells.","authors":"Xuanxuan Yao, Ruoshan Qin, Ziwei Cui, Dengqi He, Xiaorong Sun, Yuefeng Sun, Xiangyi He","doi":"10.3892/etm.2024.12783","DOIUrl":"10.3892/etm.2024.12783","url":null,"abstract":"<p><p>A human periodontal ligament cell line stably overexpressing the granulin precursor gene (<i>GRN</i>) was established through lentiviral mediation to explore the effects of <i>GRN</i> on the proliferation and osteogenic capacity of human periodontal ligament cells (hPDLCs). In the present study, a homologous recombinant lentiviral plasmid, pLV-GRN, was constructed and transfected into the hPDLCs. The expression levels of <i>GRN</i> and progranulin were assessed using reverse transcription-quantitative (RT-q)PCR and western blotting and the effect of <i>GRN</i> on the proliferative capacity was determined using the MTT assay. The osteogenic capacity of human periodontal cells overexpressing <i>GRN</i> was evaluated. The results showed that successful construction and transfection of the homologous recombinant lentiviral plasmid pLV-GRN led to the development of a stable periodontal cell line overexpressing <i>GRN</i>. The MTT assay results revealed an enhanced proliferative capacity in the pLV-GRN group compared with that in the hPDLCs and pLV-puro groups (P<0.05). Alizarin red staining and alkaline phosphatase (ALP) activity assays indicated a significantly increased osteogenic capacity in the pLV-GRN group compared with the hPDLCs and pLV-puro groups (P<0.01). RT-qPCR demonstrated strong expression of the osteogenic genes ALP, runt-related transcription factor 2 (Runx2) and osteopontin (OPN) in the periodontal cells of the pLV-GRN group (P<0.05), whereas western blotting results corroborated the high expression of the osteogenic genes Runx-2 and OPN in the periodontal cells of the pLV-GRN group (P<0.05). In summary, the overexpression of <i>GRN</i> significantly enhanced the proliferation and osteogenic capacity of hPDLCs. These findings provide an experimental foundation for periodontal tissue regeneration.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"29 2","pages":"33"},"PeriodicalIF":0.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Retracted] TIPE2 suppresses atherosclerosis by exerting a protective effect on macrophages via the inhibition of the Akt signaling pathway.","authors":"Dan Li, Ying Tan","doi":"10.3892/etm.2024.12782","DOIUrl":"https://doi.org/10.3892/etm.2024.12782","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3892/etm.2019.7316.].</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"29 2","pages":"32"},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of tigecycline for post‑neurosurgical intracranial infections due to MDR/XDR <i>Acinetobacter baumannii</i>: A retrospective cohort study.","authors":"Xia Tian, Xianbing Meng, Lichao Guo, Yan Li, Guoqing Gu, Tianyan Zhang, Rufeng An","doi":"10.3892/etm.2024.12781","DOIUrl":"10.3892/etm.2024.12781","url":null,"abstract":"<p><p>Intracranial infection is a complication of neurosurgery that can lead to severe neurological complications, greatly increasing the risk of mortality. Intracranial infection caused by multidrug-resistant <i>Acinetobacter baumannii</i> (MDR-AB) is one of the most severe complications of craniotomy. However, the availability of effective therapeutic options for such infections remains limited. Therefore, the present study aimed to assess the therapeutic efficacy of intrathecal/intracerebral (ITC) ventricle tigecycline injection for managing post-neurosurgical intracranial infections caused by MDR-AB. The present retrospective study was conducted from January 2014 to December 2023 at the Second Affiliated Hospital of Shandong First Medical University (Taian, China), which included 15 cases of MDR-AB positivity in the cerebrospinal fluid (CSF) cultures after neurosurgery. Patients treated with intravenous and intrathecal/ITC tigecycline ventricle injection were assigned to the 'ITV + ITC' group, whereas patients treated without intrathecal/ITC injection were assigned to the 'ITV' group. Data for general information, treatment history, the results of biochemical indicators in CSF and the microbiological clearance rate were collected and analyzed. No significant differences were observed in characteristics, susceptibility testing or empirical antimicrobial use between the two groups after treatment. However, after treatment, the ITV + ITC group exhibited a significantly decreased body temperature, whilst the biochemical indicators present in CSF were significantly improved. In addition, the ITV + ITC group had a significantly higher microbiological clearance rate (5/6; 83.33%) compared with that in the ITV group (2/9; 22.22%). These findings suggest that intravenous plus intrathecal/ITC ventricle injection of tigecycline is an effective regimen for treating intracranial infections caused by MDR-AB.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"29 2","pages":"31"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blockade of cysteinyl leukotriene receptor 1 alleviates asthma by inhibiting bronchial epithelial cell apoptosis and activating the Nrf2 signaling pathway.","authors":"Xiangjie Wu, Yiqiong Chen, Suping Chen, Yiping Lin","doi":"10.3892/etm.2024.12780","DOIUrl":"10.3892/etm.2024.12780","url":null,"abstract":"<p><p>The therapeutic role of blockade of cysteinyl leukotriene receptor 1 (CysLTR1) in asthma has been previously studied. However, the effect of CysLTR1 blockade on bronchial epithelial cell apoptosis and the nuclear factor erythroid-derived 2-related factor 2 (Nrf2) signaling pathway remains unclear. The present study established an ovalbumin (OVA)-induced asthmatic rat model. Varying doses (1, 4 and 30 mg/kg) of montelukast sodium, a specific CysLTR1 antagonist, were used to inhibit CysLTR1 function in an asthmatic rat model. Reverse transcription-quantitative PCR was used to detect the expression levels of CysLTR1, NAD(P)H quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1). CysLTR1 and Nrf2 protein expression levels were determined using western blotting. Immunofluorescence assays were used to evaluate the relative fluorescence intensity of Nrf2 in rat lung tissues. Lung tissue histology was assessed through hematoxylin & eosin, alcian blue and periodic acid-Schiff and Masson's trichrome staining assays. The levels of IL-17, IL-4, serum IgE and the reduced/oxidized glutathione ratio were determined using ELISA assay kits. The number of inflammatory cells was analyzed using Wright-Giemsa staining. Bronchial epithelial cell apoptosis was measured using a TUNEL assay. The results indicated that OVA-induced inflammatory responses and increased eosinophil, lymphocyte and macrophage counts were significantly attenuated following blockade of CysLTR1. Downregulated expression of antioxidant genes NQO1 and HO-1 and the reduced GSH/GSSG ratio caused by OVA challenge were restored by blockade of CysLTR1. Additionally, CysLTR1 blockade also reduced collagen deposition, suppressed goblet cell hyperplasia and inhibited bronchial epithelial cell apoptosis in a rat model of asthma. Furthermore, it was demonstrated that the blockade of CysLTR1 could significantly increase Nrf2 expression. In conclusion, the blockade of CysLTR1 could alleviate asthma in an OVA-induced rat model by inhibiting bronchial epithelial cell apoptosis and activating the Nrf2 signaling pathway. These data may potentially provide a theoretical basis for future asthma therapy in a clinical setting.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"29 2","pages":"30"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}